Stannsoporfin
Phase 2Small molecule
Stannsoporfin is one of 24 small molecule programs targeting Jaundice. It is currently in Phase 2.
2
Indications
5
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
20 competitors in Hyperbilirubinemia
#DrugCompanyPhaseTrials
1Ursodeoxycholic Acid
Daewoong Pharmaceutical Co. LTD.Approved
Immunoglobulin
SanofiApproved
Verazinc
FFakultas Kedokteran Universitas Indonesia
Phase 2
Zinc Gluconate
Johnson & JohnsonPhase 2
Abraxane
Bristol-Myers SquibbPhase 1
Gemzar
Johnson & JohnsonPhase 1
Medrol
PfizerPreclinical
Tricor
JJagotec
Preclinical
Stannsoporfin
IInfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Phase 2
Reyataz
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clinical Trial2 trials
Hyperbilirubinemia1 trial
A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
Terminated·IInfaCare Pharmaceuticals Corporation, a Mallinckrodt Company·Phase 2·NCT00850993·58 enrolled
Efficacy and Safety1 trial
Efficacy and Safety of Stannsoporfin in Neonates
Completed·IInfaCare Pharmaceuticals Corporation, a Mallinckrodt Company·Phase 3·NCT02685137·185 enrolled
Jaundice1 trial
Stannsoporfin With Light Therapy for Newborn Babies With Jaundice
Completed·IInfaCare Pharmaceuticals Corporation, a Mallinckrodt Company·Phase 2·NCT01887327·91 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Stannsoporfin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details